What is a stock summary page? Click here for an overview.
Business Description
Ironwood Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US46333X1081
Share Class Description:
IRWD: Class ACompare
Compare
Traded in other countries / regions
IRWD.USAI76.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2010-02-03Description
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.15 | |||||
| Equity-to-Asset | -0.86 | |||||
| Debt-to-Equity | -1.99 | |||||
| Debt-to-EBITDA | 6.01 | |||||
| Interest Coverage | 2.93 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | -4.23 | |||||
| Beneish M-Score | -4.3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -4.4 | |||||
| 3-Year EBITDA Growth Rate | -23.9 | |||||
| 3-Year EPS without NRI Growth Rate | -67.5 | |||||
| 3-Year FCF Growth Rate | -26 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -15.67 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.37 | |||||
| 9-Day RSI | 43.26 | |||||
| 14-Day RSI | 36.77 | |||||
| 3-1 Month Momentum % | -59.57 | |||||
| 6-1 Month Momentum % | -62.12 | |||||
| 12-1 Month Momentum % | -81.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.69 | |||||
| Quick Ratio | 4.69 | |||||
| Cash Ratio | 2.28 | |||||
| Days Sales Outstanding | 86.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.4 | |||||
| Shareholder Yield % | 24.82 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 27.24 | |||||
| Net Margin % | 0.25 | |||||
| FCF Margin % | 29.43 | |||||
| ROE % | Neg. Equity | |||||
| ROA % | 0.22 | |||||
| ROIC % | 0.38 | |||||
| 3-Year ROIIC % | 221.59 | |||||
| ROC (Joel Greenblatt) % | 152 | |||||
| ROCE % | 35.35 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | N/A |
N/A
|
N/A
| |||
| Forward PE Ratio | 5.45 | |||||
| PE Ratio without NRI | 74.04 | |||||
| Price-to-Owner-Earnings | 2.05 | |||||
| PS Ratio | 0.41 | |||||
| Price-to-Free-Cash-Flow | 1.37 | |||||
| Price-to-Operating-Cash-Flow | 1.37 | |||||
| EV-to-EBIT | 6.69 | |||||
| EV-to-EBITDA | 6.56 | |||||
| EV-to-Revenue | 1.86 | |||||
| EV-to-FCF | 6.33 | |||||
| Price-to-GF-Value | 0.1 | |||||
| Price-to-Projected-FCF | 0.13 | |||||
| Price-to-Median-PS-Value | 0.08 | |||||
| Earnings Yield (Greenblatt) % | 14.95 | |||||
| FCF Yield % | 71.93 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IRWD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ironwood Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 351.41 | ||
| EPS (TTM) ($) | - | ||
| Beta | -0.06 | ||
| 3-Year Sharpe Ratio | -1.11 | ||
| 3-Year Sortino Ratio | -1.2 | ||
| Volatility % | 65.36 | ||
| 14-Day RSI | 36.77 | ||
| 14-Day ATR ($) | 0.134736 | ||
| 20-Day SMA ($) | 1.030415 | ||
| 12-1 Month Momentum % | -81.44 | ||
| 52-Week Range ($) | 0.591 - 8.45 | ||
| Shares Outstanding (Mil) | 161.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ironwood Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ironwood Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ironwood Pharmaceuticals Inc Frequently Asked Questions
What is Ironwood Pharmaceuticals Inc(IRWD)'s stock price today?
The current price of IRWD is $0.89. The 52 week high of IRWD is $8.45 and 52 week low is $0.59.
When is next earnings date of Ironwood Pharmaceuticals Inc(IRWD)?
The next earnings date of Ironwood Pharmaceuticals Inc(IRWD) is 2025-05-09 Est..
Does Ironwood Pharmaceuticals Inc(IRWD) pay dividends? If so, how much?
Ironwood Pharmaceuticals Inc(IRWD) does not pay dividend.
Guru Commentaries on NAS:IRWD
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers